secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001213900-25-010079
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Drugs Made In America Acquisition Corp. closes $200M IPO and $4M private placement
--------------------------------------------------------------------------------

- IPO of 20,000,000 units at $10.00 each raises $200,000,000 gross proceeds.
- Sponsor purchased 400,000 private units for $4,000,000; $1,100,000 receivable noted.
- Net proceeds of $201,000,000 deposited into trust account ($10.05 per public share).
- Balance sheet shows $201M in trust, $6M deferred underwriting fees, and shareholders' deficit of $6.6M.
- Going concern warning: working capital deficit of $555,420; company must complete a business combination within 15-21 months or liquidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390025010079/0001213900-25-010079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390025010079/ea0229853-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-010079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer